Cargando…
Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials
BACKGROUND: Tralokinumab is a fully human monoclonal antibody that neutralizes the activity of interleukin‐13, a key pathogenic driver of atopic dermatitis (AD). Clinical trials including adults with moderate‐to‐severe AD, of up to 52 weeks’ duration, showed tralokinumab was efficacious and well tol...
Autores principales: | Simpson, Eric L., Merola, Joseph F., Silverberg, Jonathan I., Reich, Kristian, Warren, Richard B., Staumont‐Sallé, Delphine, Girolomoni, Giampiero, Papp, Kim, de Bruin‐Weller, Marjolein, Thyssen, Jacob P., Zachariae, Rebecca, Olsen, Christiana K., Wollenberg, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091996/ https://www.ncbi.nlm.nih.gov/pubmed/36082590 http://dx.doi.org/10.1111/bjd.21867 |
Ejemplares similares
-
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
por: Simpson, Eric L., et al.
Publicado: (2023) -
Nomenclature and clinical phenotypes of atopic dermatitis
por: Girolomoni, Giampiero, et al.
Publicado: (2021) -
Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2023) -
Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
por: Griffiths, Christopher, et al.
Publicado: (2021) -
Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
por: Soehoel, Anders, et al.
Publicado: (2022)